Novo Nordisk in the news

Novo Nordisk Shares Surge on New Obesity Drug Results

Read on: The Wall Street Journal

Eli Lilly looks set to steal Novo Nordisk's weight-loss crown

Read on: The Economist

Novo Nordisk partners with US biotech to boost pipeline of new obesity drugs

Read on: Financial Times

Eli Lilly's Zepbound beat Novo Nordisk's Wegovy in a big weight loss drug study

Read on: Quartz

Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance

Read on: CNBC News

Stocks making the biggest moves premarket: Disney, Super Micro, Novo Nordisk, Uber and more

Read on: CNBC News

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales

Read on: Morning Star

Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers

Read on: Fast Company

CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans

Read on: CNBC News

Novo Nordisk cuts forecasts after replica obesity drugs hit US take-up

Read on: Financial Times

FTSE's winning streak on par with best ever run in 2017; Novo Nordisk rises 2%

Read on: CNBC News

Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%

Read on: CNBC News

Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic

Read on: CNBC News

Novo Nordisk to continue largest insulin brand Mixtard supply in vials amid penfill device phase-out

Read on: Times of India

Denmark's Novo Nordisk sees shares tumble after competitor breakthrough

Read on: The Local

Is Novo Nordisk Stock a Buy After its Collapse?

Read on: Morning Star

Eli Lilly and Novo Nordisk are tackling heart health next

Read on: Quartz

Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly

Read on: CNBC News

Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action

Read on: CNBC News